Challenges in neurostimulation therapies have include reduced efficacy of therapy from hardware reliability, as well as the possibility of neural adaptation over time.(1) Failure rates related to product hardware (e.g. implanted leads) of up to 30% have been observed for spinal cord stimulation (SCS).(2) Many clinical indications also observe variability in the effectiveness of therapy with existing products.(3)
AdvaStim’s solution is to provide systems with disruptive technology for improving product reliability. Our pulse generator technology features a versatile design that can accommodate a variety of clinical indications. The system architecture is modular, providing a building-block approach for easy customization for each clinical indication. This strategy provides a platform for future growth and a faster track to prototype devices for newer clinical indications.
AdvaStim’s goal is to provide advanced technology for improving the patient’s quality of life.
1. Reig E, Abejon D. Spinal Cord Stimulation: a 20-Year Retrospective Analysis of 260 Patients. International Neuromodulation Society, volume 12; number 3, pp 232-239, 2009
2. Henderson J, Schade CM, Saski J, Caraway D, Oakley J. Prevention of Mechanical failures in Implanted Spinal Cord Stimulation Systems, Neuromodulation, Volume 9, number3, 183-191, 2006.
3. Mekhail NA, Mathews M, Negeeb F, Guirguis M, Mekhail M, Cheng J. Retrospective Review of 707 Cases of Spinal Cord Stimulation: Indications and Complications. Pain Practice, Volume 11, Issue 2, 2011 148-153.